Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib

Silke C Hofmann; Kristin Technau; Antonia M S Müller; Michael Lübbert; Leena Bruckner-Tuderman

doi:10.1016/j.jaad.2006.02.059

Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib

J Am Acad Dermatol. 2007 May;56(5 Suppl):S68-72. doi: 10.1016/j.jaad.2006.02.059. Epub 2006 Aug 28.

Authors

Silke C Hofmann¹, Kristin Technau, Antonia M S Müller, Michael Lübbert, Leena Bruckner-Tuderman

Affiliation

¹ Department of Dermatology, University of Freiburg Freiburg, Germany.

PMID: 17097375
DOI: 10.1016/j.jaad.2006.02.059

Abstract

Hypereosinophilic syndrome is a myeloproliferative disorder defined by unexplained, persistent hypereosinophilia with cutaneous or systemic involvement. We describe a patient with coexistence of hypereosinophilic syndrome and bullous pemphigoid. Treatment with the novel tyrosine kinase inhibitor imatinib mesylate resulted in durable remission of hypereosinophilia and skin lesions.

Publication types

Case Reports
Research Support, Non-U.S. Gov't
Review

MeSH terms

Aged
Benzamides
Humans
Hypereosinophilic Syndrome / complications*
Hypereosinophilic Syndrome / drug therapy*
Hypereosinophilic Syndrome / pathology
Imatinib Mesylate
Male
Pemphigoid, Bullous / complications*
Pemphigoid, Bullous / drug therapy*
Pemphigoid, Bullous / pathology
Piperazines / therapeutic use*
Protein Kinase Inhibitors / therapeutic use*
Pyrimidines / therapeutic use*
Treatment Outcome

Substances

Benzamides
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Imatinib Mesylate